South Africa RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
South Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$30.9 MnPlaceholder estimate
Estimate 2025$37.5 Mn0.7% of the global market
Projected 2034$213.3 Mn 468.5%Adds $175.8 Mn over 9 forecast years
CAGR 2025–203421.3%Faster than 88% of 180 Pharmaceuticals markets here
Key players5
South Africa is 0.65% of the global market.
In Africa, the largest is South Africa (this report) at $37.5 Mn.
Fastest growing: South Africa (this report) at 21.3% a year.
South Africa ranks 1st of 3 by size in Africa.
Market size projection
South Africa
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$175.8 Mn total, 2026–2034
Year-by-year market size, 2024–2034
RNA Interference Therapeutics Market market size by year, South Africa
Year
Market size
Change that year
Since 2025
2024 (estimate)
$30.9 Mn
—
—
2025 (base)
$37.5 Mn
+$6.6 Mn
—
2026 (forecast)
$45.5 Mn
+$8.0 Mn
+21.3%
2027 (forecast)
$55.2 Mn
+$9.7 Mn
+47.1%
2028 (forecast)
$67.0 Mn
+$11.8 Mn
+78.5%
2029 (forecast)
$81.2 Mn
+$14.3 Mn
+116.5%
2030 (forecast)
$98.5 Mn
+$17.3 Mn
+162.6%
2031 (forecast)
$119.5 Mn
+$21.0 Mn
+218.5%
2032 (forecast)
$145.0 Mn
+$25.5 Mn
+286.4%
2033 (forecast)
$175.9 Mn
+$30.9 Mn
+368.7%
2034 (forecast)
$213.3 Mn
+$37.5 Mn
+468.5%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
5 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The South Africa RNA Interference Therapeutics Market Analysis Executive Summary
RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.
Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).
South Africa RNA Interference Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
South Africa RNA Interference Therapeutics Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for RNA Interference Therapeutics Market in South Africa
The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for RNA Interference Therapeutics Market in South Africa
RNA Interference Therapeutics in South Africa: rules, payment and research
The South African Health Products Regulatory Authority (SAHPRA) registers medicines.[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.[2] ClinicalTrials.gov lists 5 studies on RNA Interference Therapeutics that are recruiting, active or about to start in South Africa.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Molecule
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Alnylam Pharmaceuticals
7.2 Ionis Pharmaceuticals
7.3 Arrowhead Pharmaceuticals
7.4 Novartis
7.5 Dicerna (Novo Nordisk)
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The RNA Interference Therapeutics market can be segmented based on various criteria, including molecule, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in RNA Interference Therapeutics right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
RNA Interference Therapeutics in context
South Africa compared
Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
How big is the RNA Interference Therapeutics market in South Africa?
Placeholder estimate: about $37.5 Mn in 2025, rising to about $213.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RNA Interference Therapeutics market in South Africa growing?
Placeholder estimate: about 21.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RNA Interference Therapeutics market report cover?
The report splits the market by molecule (siRNA, Antisense Oligonucleotides, microRNA), indication (Rare Genetic Diseases, Cardiovascular, Liver Diseases, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RNA Interference Therapeutics market?
Key players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis AG and Dicerna (Novo Nordisk).
What is driving the RNA Interference Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
Who regulates RNA Interference Therapeutics in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on RNA Interference Therapeutics are running in South Africa?
5 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
How much research is published on RNA Interference Therapeutics?
PubMed lists 28 papers on RNA Interference Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.